A notable example of successful multimodal fusion is KidneyIntelX.dkd, which combines TNFR1, TNFR2, KIM-1 and routine clinical variables and has received FDA De Novo authorization for assessing DKD progression risk, illustrating that such pipelines can reach clinical-grade implementation. This evidence concerns the gene HAVCR1 and diabetic kidney disease.